K
Karla V. Ballman
Researcher at Cornell University
Publications - 390
Citations - 34158
Karla V. Ballman is an academic researcher from Cornell University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 78, co-authored 353 publications receiving 29127 citations. Previous affiliations of Karla V. Ballman include University of South Florida & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer.
Abhinaba Chatterjee,Alexander E Merkler,Santosh B. Murthy,Jaclyn E Burch,Monica L. Chen,Gino Gialdini,Hooman Kamel,Karla V. Ballman,Babak B. Navi +8 more
TL;DR: Patients with cancer received intravenous thrombolysis about two thirds as often as patients without cancer among 9.5 million AIS hospitalizations, and this difference persisted over time despite increased utilization in both groups.
Journal ArticleDOI
Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations
Katie M. O'Brien,Irene Orlow,Cristina R. Antonescu,Karla V. Ballman,Linda M. McCall,Ronald P. DeMatteo,Lawrence S. Engel +6 more
TL;DR: This exploratory analysis offers novel insights into gastrointestinal stromal tumor etiology and provides a starting point for future studies of genetic and environmental risk factors for the disease.
Journal ArticleDOI
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial.
Joshua D. Palmer,Brett Klamer,Karla V. Ballman,D. D. Brown,Jane H. Cerhan,Stephen K. Anderson,Xiomara W. Carrero,Anthony Whitton,Jeffrey Greenspoon,Ian F. Parney,Nadia N. Laack,Jonathan B. Ashman,Jean-Paul Bahary,Costas G. Hadjipanayis,James J. Urbanic,Fred G. Barker,Elana Farace,Deepak Khuntia,Caterina Giannini,Jan C. Buckner,Evanthia Galanis,David Roberge +21 more
TL;DR: Overall QOL and functional independence favored SRS alone for categorical change at all time points, and intracranial tumor control, toxic effects, cognitive deterioration, and QOL was improved with WBRT.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study
Richard F. Riedel,Karla V. Ballman,Yao Lu,Steven Attia,Elizabeth T. Loggers,Kristen N. Ganjoo,Michael B. Livingston,Warren Chow,Jennifer Wright,John Harris Ward,Daniel A. Rushing,Scott H. Okuno,Damon R. Reed,David A. Liebner,Vicki L. Keedy,Leo Mascarenhas,Lara E. Davis,Christopher W. Ryan,Denise K. Reinke,Robert G. Maki +19 more
TL;DR: The results from the liposarcoma cohort of SARC024 confirm previously published data and do not support the routine use of regorafenib in this patient population, and no new significant safety signals were observed.
Journal ArticleDOI
Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study.
Kari M. Rosenkranz,Karla V. Ballman,Linda M. McCall,Colleen M. McCarthy,Charlotte Dai Kubicky,Laurie W. Cuttino,Kelly K. Hunt,Armando E. Giuliano,Kimberly J. Van Zee,Bruce G. Haffty,Judy C. Boughey +10 more
TL;DR: The Alliance Z11102 study as mentioned in this paper assessed cosmetic outcomes in women with multiple ipsilateral breast cancer treated with breast-conserving therapy (BCT) and found no significant differences in patient-reported cosmetic outcomes when stratifying by patient age, number of lesions (two or three), number of incisions, or number of lumpectomies, or size of largest area of disease.